Alerts will be sent to your verified email
Verify Email
ZIMLAB
|
Zim Laboratories
|
Trident Lifeline
|
Gennex Lab
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
R&D as a % of Total Sales
|
11.0 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
7.41 % | 31.52 % | 8.73 % |
|
5yr average Equity Multiplier
|
1.88 | 2.03 | 1.48 |
|
5yr Average Asset Turnover Ratio
|
0.94 | 0.82 | 0.67 |
|
5yr Avg Net Profit Margin
|
4.15 % | 16.21 % | 9.84 % |
|
Price to Book
|
1.41 | 4.39 | 1.48 |
|
P/E
|
53.96 | 30.19 | 18.59 |
|
5yr Avg Cash Conversion Cycle
|
37.07 Days | 61.09 Days | 55.46 Days |
|
Inventory Days
|
68.72 Days | 72.84 Days | 55.63 Days |
|
Days Receivable
|
99.71 Days | 86.3 Days | 37.35 Days |
|
Days Payable
|
143.26 Days | 122.66 Days | 68.33 Days |
|
5yr Average Interest Coverage Ratio
|
3.96 | 14.53 | 6.72 |
|
5yr Avg ROCE
|
13.52 % | 26.3 % | 11.78 % |
|
5yr Avg Operating Profit Margin
|
12.21 % | 16.98 % | 11.73 % |
|
5 yr average Debt to Equity
|
0.39 | 0.47 | 0.18 |
|
5yr CAGR Net Profit
|
10.7 % | 24.36 % | 35.01 % |
|
5yr Average Return on Assets
|
4.02 % | 13.79 % | 5.92 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
33.26 % | 63.11 % | 23.62 % |
|
Share Pledged by Promoters
|
0.0 | 3.43 % | 17.43 % |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -6.46 % | 0.24 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Zim Laboratories
|
Trident Lifeline
|
Gennex Lab
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Capex
|
Capex
|
-
|
-
|
|
Customer Segment
|
Customer Segment
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|